Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program



    TORONTO, Jan. 28 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced it has completed its Pre-IND (Investigational New Drug)
meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2,
its lead CD44 Cancer Stem Cell Program. ARH460-16-2 is an anti-cancer antibody
targeting a novel epitope of CD44 found in hematological and solid cancers,
including breast, colon and prostate. The Pre-IND meeting focused on
development plans for the drug, including manufacturing details, preclinical
pharmacology and toxicology data, and the proposed plans for the Phase I
clinical program.
    "The completion of our pre-IND meeting with the FDA is an important
milestone for the Company and demonstrates the significant progress we have
made with our lead CD44 Cancer Stem Cell Program and our ability to advance
drug candidates towards human clinical trials," said Dr. David Young,
President and Chief Executive Officer. "We are pleased with the outcome of
this meeting and will continue to prepare for our IND submission with the
intention of initiating human clinical trials this year."
    Concurrently, ARIUS announced the promotion of Susan Hahn, PhD, formerly
Director of Development, to the position of Vice President of Development.
"Dr. Hahn has been instrumental in leading the development of our antibody
programs that we are taking to the clinic," said Dr. Young. "In her new role,
Dr. Hahn will continue to focus on meeting ARIUS' development milestones as we
move each of our lead drug candidates towards human clinical trials."
    The CD44 Cancer Stem Cell program was generated using ARIUS' proprietary
FunctionFIRST(TM) technology, which selects antibodies based on their ability
to kill cancer cells. Pre-clinical data from a dose-ranging pilot toxicology
study in non-human primate models demonstrated no dose-limiting toxic effects
at doses up to 95 mg/kg and significant tumor growth inhibitory activity in in
vivo animal models of breast, prostate, liver and AML cancers. The Company
will now complete manufacturing and advanced toxicology studies toward filing
the IND later this year.

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than
500 antibody candidates. In addition to the antibodies it is developing
in-house, ARIUS has ongoing partnerships with key biotechnology and drug
development companies. ARIUS is listed on the TSX under the symbol "ARI". For
further information, visit www.ariusmabs.com

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    %SEDAR: 00013708E




For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
wwhitehead@ariusmabs.com, contact@ariusmabs.com; James Smith, Investor
Relations, (416) 815-0700 ext. 229, jsmith@equicomgroup.com

Organization Profile

ARIUS RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890